• Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Menu
  • Home
  • History
    • Introduction
    • The Aspirin Story
    • Timeline
    • Chemistry
  • Advisory Board
  • Awards
  • Conferences
  • Scientific Information
    • Guidelines
    • Disease Prevention
    • Aspirin Summaries
    • Aspirin Matters
  • News
  • Contact
Search
Close

Enter Senior Science Award

Applications Are Invited For The International Aspirin Foundation’s Senior Science Award 2020

Biomedical researchers with a long-term interest in aspirin are invited to apply for the International Aspirin Foundation’s Senior Science Award 2020.

Designed to recognise and encourage research into different uses for aspirin, the biennial award is widely considered the most prestigious in its field.

Professor Carlo Patrono, MD, FESC, FRCP, Chair of the International Aspirin Foundation’s Scientific Advisory Board will lead the judging process. He said: “The Senior Science Award is a recognition of those scientists who have contributed innovative basic or clinical research elucidating mechanistic and/or therapeutic aspects of aspirin’s multifaceted benefits”.

“We welcome entries from individuals and groups with a record of outstanding biomedical research that has advanced the scientific knowledge of aspirin and its impact on human health, and look forward to celebrating the best in the field.”

Past winners of the Senior Science Award include Professor Peter Rothwell for his research evidencing a substantial role of aspirin in the reduction of cancer incidence, metastasis and mortality; Professors Nancy Cook, Michael Gaziano and Julie Buring for their pioneering long term randomised trials of aspirin in the prevention of vascular events and other pathology; and Professor Paola Patrignani for her life-long work in the field of arachidonic acid metabolism and the pharmacology of antiplatelet and anti-inflammatory drugs.

Supported by Bayer AG and offering a £20,000 endowment, this year’s award will be presented in the prestigious Ether Dome Amphitheatre at Massachusetts General Hospital, Boston on 28th September 2020.

The application deadline is 31 March 2020. Applicants are asked to submit up to a 1000-word summary of their career and contribution to the use and science of aspirin, together with a 200 word lay summary. Winners will be notified by 30 April.

Senior Aspirin Award Criteria
  • Use and science of aspirin, together with a 200 word lay summary.
  • Applicants should have a demonstrable track record of valuable biomedical research (basic, clinical or translational), contributing to the scientific knowledge of aspirin.
  • Deadline for receipt of applications is 31st March 2020. All applications will be reviewed by the International Aspirin Foundation Scientific Advisory Board in reaching their decision.
  • In recognition of the chosen applicant(s)’ achievements, there will be a presentation ceremony to honour their work.
  • Applicants should be available to attend an Award Ceremony in Boston and be prepared to participate in media interest in the event. In addition the lay summary will be used for publicity purposes.
  • A report will be produced on the awardee(s)’ body of work.
Application
Award entries are invited from a potential candidate or his/her colleagues by their colleagues in scientific or academic institutions, together with a short (1,000 word) summary in the terms covered in the Award Criteria and a lay summary (200 words).
Submission method
  • Applications should be sent via email.
  • Email: awards@aspirin-foundation.com

Deadline

Applications are to be received by 31st March 2020. An email or letter will be sent confirming receipt and validity.

Review Process
  • The Secretariat will provide the list of candidates for the Scientific Advisory Board at the March Board Meeting. The Scientific Advisory Board may nominate additional candidates.
  • All applications will be reviewed and a decision made. The Scientific Advisory Board will seek to achieve unanimity in selection.

In all matters pertaining to the Science Award, the decision of the Chair of the SAB is final.

Award winner(s) will be notified by 30th April 2020.

Previous Winners
  • Bayer Senior Aspirin Award:

    • 1992 – Garret Fitzgerald
    • 1995 – Gustav Born
    • 1996 – Henry Barnett
    • 1997 – William Smith
    • 1998 – Carlo Patrono
    • 1999 – Charles Hennekens
    • 2000 – Sir Richard Peto, Colin Baigent, Rory Collins, and Peter Sleight
    • 2002 – Aaron Marcus
    • 2007 – Hans Christoph Diener

    International Aspirin Foundation winners:

    • 2014 Peter Rothwell, Oxford UK
    • 2016 Julie Buring/Nancy Cook/Mike Gaziano, Boston USA
    • 2018 Paola Patrignani, Italy
Current Endowment
  • £20,000 per individual or group

Connect with us

Sign up to be part of the aspirin community and be the first to receive latest information.

Sign up to be part of the aspirin community and be the first to receive latest information.

Contact Us Here
Footer Logo
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
Menu
  • Terms & Conditions
  • Branding Guidelines
  • Privacy
  • Cookie Policy
  • Disclaimer
Twitter
Linkedin

Copyright © 2020 Aspirin Foundation

Website by mtc.

Djp

Daniel José Piñeiro

ASSOCIATE
Name
Daniel José Piñeiro
Academic Affiliations:
Full Professor of Medicine, Universidad de Buenos Aires, Argentina Trustee, Board of Trustees, American College of Cardiology
Professional Setting:
My academic experience includes more than 40 years as a practicing medical doctor, teacher, and researcher. I have fulfilled these appointments in settings of vital social engagement and impact, most notably at the Hospital de Clínicas “José de San Martín” of the Universidad de Buenos Aires, a public hospital with high academic recognition. Additionally, I currently hold the position of Full Professor of Medicine at that same University.
Academic Activities:
  • International Meetings Participations: 180
  • Books-Editor: 1
  • Books Chapters: 39
  • Refereed Full Articles: 118 (listed in Pubmed: 29)
  • Refereed Abstracts: 221
  • Editorial Boards: 10
Profesional Associations:
  • 2005 President, Sociedad Argentina de Cardiología.
  • 2011-2013 President, Inter-American Society of Cardiology.
  • 2011-2013 Member (ex-officio), Board of Directors, World Heart Federation
  • 2017-2018 Member (at large), Board of Directors, World Heart Federation
  • 2018-2021 Trustee, Board of Trustees, American College of Cardiology
Return to Scientific Advisory Board
Chia

John Chia

Name
John Chia MBBS (Spore), MRCP (UK), FAMS (Spore)
Academic Affiliations:

Adjunct Associate Professor DUKE-NUS Graduate Medical School,
Consultant Oncologist Curie Oncology Singapore,
Visiting Consultant National Cancer Centre Singapore.

Discipline:

Medical Oncology

Scientific Interests:
  • Aspirin as adjuvant therapy in established cancers
  • Adoptive T cell therapy and Dendritic cell vaccines in the treatment of solid tumors
  • Clinical Trial Design and Management
Declaration of Conflicts of Interest:

In the past 3 years, I have received consultant fees from Tessa Therapeutics, Aslan Pharmaceuticals, Novartis, and AstraZeneca.

I received grant support for investigator-initiated research from:

  • National Medical Research Council Singapore
  • Bayer AG

I hold shares in:  Roche, BMS, AstraZeneca, Incyte, Teva Pharmaceuticals, Trillium Therapeutics, Compugen, Arrowhead pharmaceuticals, Emergex, QuantumDx and Halozyme Therapeutics

Return to Scientific Advisory Board
Badimon

Lina Badimon

Name
Lina Badimon BSc, PharmD, PhD, FESC, FAHA
Academic Affiliations:
Director of the Cardiovascular Science Program (ICCC) at the Hospital Santa Creu and San Pau, IIB-Sant Pau; CIBER CV. Director of the Cardiovascular Research Chair of the Autonomous University of Barcelona and Director of the UNESCO Chair in Biomedical Sciences Training and Research.
Discipline:
Pharmacology, Cardiovascular Disease
Scientific Interests:
Cardio-metabolic diseases, thrombosis, atherosclerosis and ischemic heart disease
Declaration of Conflicts of Interest:

I received consultant and speakers fees from Amgen, AstraZeneca, Bayer, Lilly and Sanofi.

    Return to Scientific Advisory Board
    Ge

    Junbo Ge

    Name

    Junbo Ge

    Ge Junbo, male, was born in Wulian, Shandong province on Nov. 8, 1962. He is the member of Chinese Academy of Sciences, professor and doctoral supervisor. He received his doctor’s degree of Medicine from German Mayence University in 1993 and now works as the director for Shanghai Institute of Cardiovascular Disease and the Center for Stem Cells and Tissue Engineering, Fudan University. He is also the designate chairman of the Cardiovascular Disease Branch of Chinese Medical Association, council member of the Cardiovascular Angiography and Interventions Association, international consultant of the American Heart Association. In Dec. 2013, he was appointed as the vice president of Tongji University.

    Prof. Ge has been engaged in clinical and scientific research work of cardiovascular disease since 1987, and his research area covers the pathogenesis of coronary heart disease, early diagnosis and treatment plan optimization.

    Return to Scientific Advisory Board
    Langley

    Ruth Langley

    Name
    Ruth Langley PhD, FRCP
    Academic Affiliations:
    Professor of Oncology and Clinical Trials, MRC Programme Leader and Chair of the Cancer Group, MRC Clinical Trials Unit at UCL, honorary consultant in medical oncology at the Brighton and Sussex University Hospital.
    Discipline:
    Medical oncologist; trialist
    Scientific Interests:
    • Aspirin
    • Gastro-oesophageal malignancy
    • Transdermal oestrogen in the treatment of prostate cancer
    • Trials methodology
    Declaration of Conflicts of Interest:
    Has received honorarium from Bayer
    Return to Scientific Advisory Board
    Chan

    Andrew T Chan

    Name
    Andrew T. Chan MD, MPH
    Academic Affiliations:
    Chief, Clinical and Translational Epidemiology Unit, Vice Chair, Division of Gastroenterology, Massachusetts General Hospital, Boston, Co-leader, Cancer Epidemiology Program, Dana-Farber/Harvard Cancer Center, Boston.
    Discipline:
    Gastroenterology
    Scientific Interests:
    • The role of aspirin in the prevention of colorectal cancer and other cancers
    • The role of the gut microbiome in colorectal cancer and other chronic gastrointestinal diseases, including inflammatory bowel disease and diverticulitis
    • The role of diet and lifestyle in colorectal cancer and other chronic gastrointestinal cancers
    Declaration of Conflicts of Interest:

    AACR Honors Dr. Andrew T. Chan With 2019 AACR-Waun Ki Hong Award

    Click here to find the press release.

    I received consultant Bayer and Pfizer, Inc.

    I received grant support for investigator-initiated research from:

    • National Institutes of Health
    • National Cancer Institute
    • Crohn’s and Colitis Foundation
    • Bayer AG
    Return to Scientific Advisory Board
    Gaziano

    Mike Gaziano

    Name
    J Michael Gaziano MD, MPH
    Academic Affiliations:

    Professor of Medicine, Harvard Medical School; Chief Division of Aging, Brigham and Women’s Hospital; Director of Preventive Cardiology and Director of Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), VA Boston Healthcare System.
    Discipline: Cardiology and Epidemiology

    Scientific Interests:
    I am a chronic disease epidemiologist with a particular interest in the roles that individual lifestyle choices (diet, exercise, smoking), metabolic factors (obesity, high cholesterol, and hypertension), and biochemical and genetic markers play on the risk of cardiovascular disease and other chronic illnesses. Also, of interest is the impact that vascular disease has on other organ systems, including cognitive dysfunction and renal disease. I have an interest in the design of large-scale trials and observational studies nested in large health care systems using big data analytic techniques.
    Declaration of Conflicts of Interest:

    I received consultant and speaker fees Bayer.

    I received grant support as a principal investigator or co-investigator for research from the VA, DOD, NIH, Merck and Kowa.

    Return to Scientific Advisory Board
    Rothwell

    Peter Rothwell

    PAST – CHAIR
    Name

    Peter M. Rothwell PhD, MD, FRCP, FMedSci

    Academic Affiliations:
    • Action Research Chair of Neurology, Nuffield Department of Clinical Neurosciences, University of Oxford;
    • Founding Director, Wolfson Centre for Prevention of Stroke and Dementia, University of Oxford;
    • Wellcome Trust Senior Investigator;
    • Emeritus NIHR Senior Investigator;
    • Theme Leader, Stroke and Vascular Dementia, NIHR Biomedical Research Centre, John Radcliffe Hospital, Oxford
    Discipline:
    Neurology and Stroke Medicine
    Scientific Interests:
    • Risks and benefits of aspirin;
    • Primary and secondary prevention of stroke;
    • Effects of blood pressure on the brain.
    Declaration of Conflicts of Interest:
    I received consultant and speakers fees from Bayer AG.
    Return to Scientific Advisory Board

    Carlo Patrono

    CHAIR
    Name
    Carlo Patrono MD, FESC, FRCP
    Academic Affiliations:
    Adjunct Professor of Pharmacology at the Catholic University School of Medicine in Rome (Italy) and at the Perelman School of Medicine of the University of Pennsylvania in Philadelphia (USA).
    Discipline:
    Clinical Pharmacology
    Scientific Interests:
    • Studying platelet activation and inhibition in diabetes mellitus
    • Studying platelet activation and inhibition in myeloproliferative neoplasms
    • Investigating the mechanism of action of low-dose aspirin in preventing colorectal cancer
    Declaration of Conflicts of Interest:

    I received consultant and speakers fees from Acticor Biotech,  Amgen,  Bayer, GlaxoSmithKline,  Tremeau,  Zambon.

    I received grant support for investigator-initiated research from:

    • AIFA (Italian Drug Agency)
    • Bayer AG
    • Cancer Research UK
    • European Commission, FP6 and FP7 Programmes

      Return to Scientific Advisory Board

      Have something to say about aspirin?

      We would like to hear from you and have a chat, and maybe feature you on our podcast. Please fill in the form below and we will contact you with further information.